SGIOY Overview

Investment Agreement: Shionogi has signed a $300 million loan agreement to support additional investments in ViiV Healthcare.

Focus on Healthcare: The investment aims to enhance ViiV Healthcare's capabilities and offerings in the healthcare sector.

Shionogi & Co. Financial Performance: The company reported a profit before tax of ¥46.3 billion and revenue of ¥99.8 billion for Q1.

Licensing Expansion: ViiV has expanded its license to produce the generic version of Apretude in low-income countries.

HIV Treatment Development: ViiV Healthcare reported promising results from phase 2 trials for two HIV antiretroviral candidates, VH184 and VH499, which showed significant declines in HIV-1 viral load with various oral dosages.

Long-Acting Formulations: The data supports the potential of VH184 as a long-acting treatment, with ongoing evaluations in phase 1 studies for its long-acting formulations.

Financial Performance: Shionogi & Co. reported Q3 FY2024 revenue of JPY333.6 billion, a slight year-over-year decrease, but an increase when excluding a one-time payment from the previous year. The HIV business showed strong growth, particularly in long-acting formulations, while domestic infectious disease treatments stabilized.

Strategic Outlook: The company plans to focus on expanding its quality of life (QOL) disease portfolio and has dissolved its joint venture with Ping An Insurance to accelerate drug launches in China. Management remains confident in achieving a revenue target of JPY550 billion for FY2025, despite concerns over market volatility and regulatory challenges.

Financial Performance: Shionogi & Co. reported H1 revenue of 214 billion yen, but experienced a 22.7% decrease in operating profit to 75.9 billion yen.

Profit Decline: The company's profit before tax fell by 18.8% year on year, totaling 93.8 billion yen.

Trial Results: A head-to-head trial showed that ViiV Healthcare's Dovato is as effective as Gilead Sciences' Biktarvy in treating HIV, with Dovato resulting in less weight gain over 48 weeks.

Weight Gain Comparison: Patients on Biktarvy experienced a greater average weight increase (1.81kg) compared to those on Dovato (0.89kg), with a higher percentage of Biktarvy patients gaining more than 5% of their body weight.